Pharmaceuticals

Specific Antiviral Drugs For COVID 19 Market Size and Growth Forecast for Businesses 2025–2029

November 14, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Are The Current (2025) And Forecast (2029) Sizes Of The Specific Antiviral Drugs For COVID 19 Market?

The market size for specific antiviral drugs targeting Covid-19 has experienced rapid expansion in recent years. It is projected to expand from $13 billion in 2024 to reach $15.23 billion in 2025, driven by a compound annual growth rate (CAGR) of 17.1%. Historically, this growth has been attributed to factors such as rising hospitalization due to severe cases, increasing government funding for antiviral research, a growing preference for targeted therapeutics over generic treatments, rising awareness regarding early antiviral intervention, and increasing collaborations among pharmaceutical companies.

The specific antiviral drugs for covid 19 market size is anticipated to experience substantial growth over the next few years, projected to reach $28.43 billion by 2029 with a compound annual growth rate (CAGR) of 16.9%. This expansion during the forecast period can be attributed to a heightened focus on pandemic preparedness, an increasing number of clinical trials, a growing demand for effective COVID-19 treatment options, the rising prevalence of COVID-19 variants, and the expanding acceptance of oral antiviral therapies. Significant trends expected during this period include innovation in broad-spectrum antiviral formulations, the integration of artificial intelligence into drug discovery, advancements in personalized antiviral therapies, novel approaches in combination therapy, and the incorporation of genomic data to target viral mutations.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24713&type=smp

What Are The Key Drivers Of Growth In The Specific Antiviral Drugs For COVID 19 Market?

An increase in COVID-19 cases is anticipated to drive future expansion within the specific antiviral drugs for the COVID-19 market. COVID-19 cases are defined as individuals confirmed to be infected with the SARS-CoV-2 virus, the causative agent of COVID-19. This surge in COVID-19 cases stems from the appearance of novel variants capable of more facile transmission and partial evasion of immunity acquired from vaccinations or previous infections. These specialized antiviral medications for COVID-19 play a role in lessening the illness’s intensity and length, thereby enhancing patient recovery and decreasing the total impact of COVID-19 cases. To illustrate, data from May 2023, provided by the US government’s Centers for Disease Control and Prevention, showed that COVID-19 fatalities with co-existing causes averaged 4.5 contributing conditions in 2022, an increase from 4.2 in 2021. Consequently, the expanding volume of COVID-19 infections fuels the development of the specific antiviral drugs for the COVID-19 market.

What Are The Key Segments In The Specific Antiviral Drugs For COVID 19 Market?

The specific antiviral drugs for covid 19 market covered in this report is segmented –

1) By Type: Tablet, Injection

2) By Indication: Hospitalized Patients, Non-Hospitalized Patients, Preventive Treatment

3) By Drug Class: Nucleoside Analogues, Protease Inhibitors, Ribonucleic Acid Polymerase Inhibitors, Entry Inhibitors, Monoclonal Antibodies

4) By Route Of Administration: Oral, Intravenous, Subcutaneous, Inhalation

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments

1) By Tablet: Oral Antiviral Tablets, Combination Antiviral Tablets, Extended-Release Tablets

2) By Injection: Intravenous (IV) Antiviral Injections, Intramuscular (IM) Antiviral Injections, Subcutaneous Antiviral Injections

What Are The Latest Industry Trends Transforming The Specific Antiviral Drugs For COVID 19 Market?

Leading companies operating within the specific antiviral drugs for the COVID-19 market are concentrating on developing novel treatments, particularly oral antiviral therapies, to enhance both the availability and efficacy of care. Oral antiviral therapies are medications consumed by mouth designed to halt the replication of viruses such as COVID-19, presenting a practical and potent treatment solution. As an illustration, in January 2022, Lupin Limited, an India-based pharmaceutical company, launched the antiviral medication Molnupiravir under the brand name Molnulup, aimed at treating high-risk adult patients afflicted with COVID-19. This oral drug is intended for adults experiencing mild to moderate COVID-19 who are prone to developing severe illness. Molnupiravir functions by preventing the SARS-CoV-2 virus from replicating, thereby contributing to a reduction in viral load and disease severity. Its maximum effectiveness is observed when administered within five days of symptom appearance, proving especially beneficial for individuals with co-existing conditions like obesity, advanced age, diabetes, or cardiovascular disease.

Which Industry Leaders Are Driving Innovation Across The Specific Antiviral Drugs For COVID 19 Market?

Major companies operating in the specific antiviral drugs for covid 19 market are Pfizer Inc., Johnson and Johnson, Roche Holding AG, Merck And Co. Inc., Novartis AG, GSK plc, Eli Lilly and Company, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc, Hetero Drugs Limited, Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Limited, Beximco Pharmaceuticals Limited, BioCryst Pharmaceuticals Inc., Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Aligos Therapeutics Inc., Synairgen plc

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/specific-antiviral-drugs-for-covid-19-global-market-report

Which Region Currently Holds The Largest Share Of The Specific Antiviral Drugs For COVID 19 Market?

North America was the largest region in the specific antiviral drugs for COVID 19 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specific antiviral drugs for covid 19 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Specific Antiviral Drugs For COVID 19 Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24713&type=smp

Browse Through More Reports Similar to the Global Specific Antiviral Drugs For COVID 19 Market 2025, By The Business Research Company

Antivirals Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

The Antiviral And Antimicrobial Coatings Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/the-antiviral-and-antimicrobial-coatings-global-market-report

Antiviral Combination Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795